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Abstract
Metabolic modifications of tumor cells are hallmarks of cancer. They exhibit an altered metabolism that allows them to
sustain higher proliferation rates in hostile environment outside the cell. In thyroid tumors, the expression of the estrogen-
related receptor a (ERRa), a major factor of metabolic adaptation, is closely related to the oxidative metabolism and the
proliferative status of the cells. To elucidate the role played by ERRa in the glycolytic adaptation of tumor cells, we focused
on the regulation of lactate dehydrogenases A and B (LDHA, LDHB) and the LDHA/LDHB ratio. Our study included tissue
samples from 10 classical and 10 oncocytic variants of follicular thyroid tumors and 10 normal thyroid tissues, as well as
samples from three human thyroid tumor cell lines: FTC-133, XTC.UC1 and RO82W-1. We identified multiple cis-acting
promoter elements for ERRa, in both the LDHA and LDHB genes. The interaction between ERRa and LDH promoters was
confirmed by chromatin immunoprecipitation assays and in vitro analysis for LDHB. Using knock-in and knock-out cellular
models, we found an inverse correlation between ERRa expression and LDH activity. This suggests that thyroid tumor cells
may reprogram their metabolic pathways through the up-regulation of ERRa by a process distinct from that proposed by
the recently revisited Warburg hypothesis.
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Introduction
The estrogen-related receptor alpha (ERRa) is an orphan
nuclear receptor involved in the regulation of mitochondrial
biogenesis through the oxidation of fats and glucose [1–3].
Recently, ERRa has also been considered as a switch regulating
not only the mitochondrial function but also glycolysis so as to
maintain a steady level of ATP production, particularly when
mitochondrial biogenesis is decreased [4–5]. ERRa binds to the
ERR response element (ERRE) leading to the regulation of the
cellular energy metabolism according to endogenous or exogenous
stimuli [2,6,7]. This transcription factor may interfere with the
three transcriptional coactivators of the PGC-1 family, i.e. the
PPARc coactivator-1a (PGC-1a), the PPARc coactivator-1b
(PGC-1b) and the PGC-1-related coactivator (PRC), all of which
serve as mediators between the environment and the transcrip-
tional machinery. PGC-1a and PGC-1b are mainly associated
with the modulation of metabolic pathways in tissues that require
high oxidative energy production, such as the heart and skeletal
muscle [8]. Unlike PGC-1a and PGC-1b, PRC is ubiquitous and
more abundantly expressed in proliferating cells. Recent report on
deficient PRC mice underlines the non redundant role for this
coactivator related to others members of the family [9]. We have
shown that the ERRa-PRC transcriptional complex plays
a consistent role in thyroid proliferative cells by increasing the
coupling efficiency of mitochondria in oxidative cells, and through
some other pathway in glycolytic cells [6]. The implication of
PRC-ERRa complex in the direct regulation of key enzymes of
the glycolytic pathway, such as lactate deshydrogenase (LDH),
needs to be investigated.
LDH is a tetrameric enzyme composed of two subunits, M and
H, encoded by the LDHA and LDHB genes respectively. Each
subunit has specific kinetic properties with LDHA being usually
associated with pyruvate-to-lactate conversion, and LDHB with
lactate-to-pyruvate conversion [10,11]. The combination of
subunits results in five isozymes (A4, A3B1, A2B2, A1B3, and
B4) with tissue-specific distribution [10]: the isoenzymes contain-
ing large proportions of LDHB tend to predominate in tissues with
aerobic metabolism (e.g. heart) while those containing mainly
LDHA are found in tissues with considerable anaerobic metab-
olism (e.g. skeletal muscle and liver). In addition, the ratio LDHA/
LDHB may have significant physiological effects on the isoenzyme
pattern. The level of LDHA is elevated in many cancers and plays
a crucial part in tumor progression, but the link between invasive
tumor development and glycolysis is poorly understood. The role
of LDHB in tumor development is less well characterized [12].
Down-regulation of LDHB has a greater effect on lactate
production than the induction of LDHA [13,14]. The modulation
of the expression of LDHB could maintain the mitochondrial
defect that contributes to the invasiveness of cancer. Moreover,
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LDHB has been identified as a direct downstream target of the
PI3K/AKT/mTOR pathway and should be considered as
a therapeutic target of interest for tumors with a high potential
of invasiveness [15].
Considering the crucial role of ERRa and the PGC-coactivator
family in the regulation of metabolic pathways, their implication in
the metabolic switch often associated with tumor progression
needs to be investigated. We studied 30 thyroid tumors and three
human thyroid tumor cell lines, i.e. FTC-133, XTC.UC1 and
RO82W-1, to investigate the role of ERRa in the integrative
regulation of the glycolytic metabolism and cell proliferative status.
Materials and Methods
Tissue Samples
The study was approved by the ethics committee at the
University Hospital of Angers (France), and all patients gave
written informed consent. Samples, rendered anonymous before
beginning the study, consisted of 10 classical follicular thyroid
tumors, 10 oncocytic variant of thyroid tumors and 10 normal
thyroid tissues. All samples were obtained from the Ambroise Pare´
Hospital (Paris, France).
Cell Cultures
Three human follicular thyroid carcinoma cell lines were used:
the XTC.UC1 cells were oncocytic variants kindly provided by O.
Clark [16], and the other cell lines, FTC-133 and RO82 W-1,
were obtained from the Interlab Cell Line Collection (National
Institute for Cancer Research, Genoa, Italy) and originated from
classical follicular carcinomas.
FTC-133 and XTC.UC1 cells were grown in Dulbecco’s
modified medium (Invitrogen Corp., Carlsbad, CA, USA),
supplemented with 10% fetal bovine serum (Seromed, Biochrom
AG, Berlin, Germany), 1% L-glutamine (Invitrogen, Carlsbad,
CA, USA) and 1% penicillin/streptomycin (Invitrogen, Carlsbad,
CA, USA). We added 10 mU/ml TSH (Sigma-Aldrich, Saint
Louis, MO, USA) for XTC.UC1.
RO82 W-1 cells were grown in 60% Dulbecco’s modified
medium, and 30% endothelial basal medium (both from PAA,
Pasching, Austria) supplemented with 10% fetal bovine, 1% L-
glutamine, and 1% penicillin/streptomycin.
For treatment with the inverse agonist XCT790 (Sigma-Aldrich,
Saint Louis, MO, USA) was used a concentration validated for its
specific ERRa inhibition in our cellular models [6]. FTC-133 and
RO82W-1 cells were treated for 10 days with a final concentration
of 5 mM XCT790, replaced with fresh media every three days.
Bioinformatics Analysis of LDH Promoters
We extracted LDHA and LDHB promoter sequences from
nucleotides 22000 to 21 starting from the transcription starting
site (TSS) according to the NCBI accession NM_00566 and
NM_002300. We scanned the promoters with the Matrix-Scan
software (http://rsat.ulb.ac.be/rsat/) using a position-weight
matrix defining ERRa binding sites as described elsewhere [17].
The transcription-factor binding site representations were consid-
ered statistically significant at 5% risk after simultaneous
comparison with a set of 100 human promoters.
ERRa Chromatin Immunoprecipitation (ChIP)
ERRa-ChIP assays were performed on 106 XTC.UC1 cells/
assay using an anti-human ERRa antibody (sc-65714 from Santa
Cruz, CA, USA) according to the protocol provided by the
manufacturer (EZ-ChIP, Upstate, Millipore, Billerica, MA, USA).
A rabbit anti-goat IgG (55335, MP Biomedicals, CA, USA) was
used as a control of non-specific immunoprecipitation. Pellets were
dissolved in water and quantitative PCR reactions were performed
on the immunoprecipitates and the input DNA using the following
primers designed for LDHA and LDHB genes:
LDHA: 59-TTGAAGGGAGAGATGATGGA-39 and 59-
CCAGCCGTGATAATGACCAG-39
LDHB: 59-TGCTCTTGTGGATGTTTTGG-39 and 59-
CTCTCCCCTTCTTGCTGACG-39
ChIP was considered positive when the gene expression was
enriched at least 3-fold in the IgG fraction following the 22DDCT
method [18].
Cloning of the Human LDHB Promoter and Construction
of the Reporter Plasmids
LDHB promoter reporter plasmids were constructed using
a human genomic DNA fragment from the 59-flanking region of
the human LDHB promoter to the TSS as matrix. To generate
the different constructions of the reporter plasmids p.LDHB-Luc
1188, p.LDHB-Luc 611, p.LDHB-Luc 515 and p.LDHB-Luc 105,
we amplified the LDHB promoter using the same reverse primer
(59-AAGCTTCTACCAGGAGAGAGAAGGCT-39) and forward
primers as follows:
p.LDHB-Luc 1188: 59-AGATCTGGCACTGAGAA-
TAAACTGAA-39,
p.LDHB-Luc 611: 59-AGATCTCTGTAATCCCAG-
CACTTTGG-39,
p.LDHB-Luc 515: 59-AGATCTCCCCTCTCTACTAAAAA-
TAC-39,
p.LDHB-Luc 105: 59-AGATCTTGAAGGGGATTGAGC-
GAG-39.
PCR products were doubly digested with Bgl2 and HindIII and
inserted into the pGL3-basic vector. The identity of the
constructions was confirmed by sequencing.
Transient Transfections and Luciferase Assay
RO82W-1 cells were plated two days before transfection.
Transient transfection was performed with lipofectamine (Invitro-
gen, Carlsbad, CA, USA) as recommended by the manufacturer.
Cells were collected 48 h later for functional and quantitative PCR
analyses.
According to the experiments, RO82W-1 cells were transfected
with 1 mg LDHB promoter reporter plasmid (p.LDHB Luc),
0.05 mg of plasmid PRC (Origene Technologies, Rockville, MD,
USA), 0.05 mg of plasmid ERRa (Addgene, Cambridge, MA,
USA) and 0.5 mg of pRL-CMV (Promega, Madison, WI, USA)
used as an internal control of transfection efficiency.
For experimentation with luciferase activity, cells were har-
vested after 48 h of treatment for the luciferase reporter assay
using the Dual-Luciferase Reporter Assay System (Promega).
Luciferase activity was normalized to that of the internal control,
Renilla luciferase, used as the relative luciferase unit. All assays
were done in duplicate in three separate experiments.
siRNA
To knock down ERRa expression in FTC-133 cells, we
transfected predesigned ERRa siRNAs (s4830) and scrambled
control siRNA (AM4635) with siPORT NeoFX. After 48 h, cells
were harvested for assays. All cells were tested for the down-
expression of ERRa, and siRNA was considered efficient when the
ERRa expression was inhibited by at least 70% compared to
scramble control.
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Western Blot
Cells were rinsed in PBS, trypsinized and collected in centrifuge
tubes. Proteins (20mg) were separated by SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes (Hybond-P, Amer-
sham International plc, Little Chalfont, UK) by electroblotting.
The membranes were incubated in 5% non-fat milk in TBS-
Tween (tris-buffered saline (TBS) with 0.1% Tween-20). The
membranes were incubated overnight with dilutions (1/2000) of
the following antibodies: monoclonal anti- b-Actin, anti-LDHA,
anti-LDHB and anti-ERRa (all obtained from Abcam, Cam-
bridge, UK). After several washes in TBS-Tween, the membranes
were incubated with an appropriate chemiluminescent-labelled
horseradish peroxidase-conjugated secondary antibody (Jackson
ImmunoResearch, WestGrove, PA, USA). The blots were de-
veloped using the enhanced chemiluminescence method (ECL-
plus, Amersham Pharmacia Biotech, Buckinghamshire, UK).
Signal quantification was performed by non-saturating picture
scanning by a gel Doc 1000 Molecular Analyst apparatus (Biorad,
Hercules, CA, USA).
Quantitative RT-PCR Analyses
Total RNA was isolated using the RNeasy kit (Qiagen, Hilden,
Germany) for cultured cells, and trizol procedure for thyroid
tissues (Invitrogen).
Reverse transcription was performed on 1 mg of RNA with
Advantage RT-for-PCR kit (Clontech, Palo Alto, CA, USA)
following the manufacturer’s recommendations.
Figure 1. Metabolic analysis for the three cell lines: FTC-133, XTC.UC1, RO82W-1, and 30 thyroid tissues (10 controls, 10 follicular
tumors and 10 oncocytic tumors). Relative expression levels of LDHA, LDHB and ERRa determined by quantitative PCR and normalized to b-globin
for cell lines (A) and thyroid tissues (B). Ratio of expression level of LDHA to LDHB for cell lines relative to FTC-133 (C) and for thyroid tissues relative to
control tissues (D); Ratio of LDH to CS activities for cell lines (E) and thyroid tissues (F); Measurement of oxygen consumption under basal respiratory
conditions for cell lines (G) and thyroid tissues (H). Results are the mean values6SD of three experiments for the cell lines and mean values of thyroid
tumors relative to control thyroid tissues.& p,0.05 for FTC-133 versus XTC.UC1 or RO82W-1,% p,0.05 for XTC.UC1 versus RO82W-1, m p,0.05 for
control thyroid versus follicular tumors or oncocytic tumors; D p,0.05 for follicular tumors versus oncocytic tumors.
doi:10.1371/journal.pone.0058683.g001
Figure 2. Potential ERRa response elements in LDHB and LDHA promoters (A) Potential ERRa binding sites numbered relative to the
transcription starting site (TSS) (B) Chromatin ImmunoPrecipitation (ChIP) assay for LDH promoters in XTC.UC1 cells using
a polyclonal ERRa antibody. Chromatin was immunoprecipitated with the indicated antibody and submitted to quantitative PCR. Results are
expressed as fold change of enrichment compared to control IgG immunoprecipitated material. ERRa-IP was realized in duplicate and each sample
was tested in triplicate for quantitative PCR. TFBS: transcription factor binding site.
doi:10.1371/journal.pone.0058683.g002
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Real-time quantification was performed in a 96-well plate using
the IQ SYBR Green SuperMix and Chromo4 (Biorad). Data were
normalized to b-globin as described elsewhere [6].
Respiratory Parameters
Respiratory parameters were investigated on intact cells from
cultured cell lines and sample tissues by polarography, using
a high-resolution Oroboros O2k oxygraph (Oroboros Instruments,
Innsbruck, Austria) as described elsewhere [19,20]. The basal
respiratory rate, defined as respiration in the cell-culture medium
without additional substrates or effectors, was determined by
measuring the linear rate of oxygen flux in intact cells (3.106 cells
placed at 37uC in 2 ml Dulbecco’s modified medium).
Enzymatic Activities
The activity of citrate synthase (CS), and Lactate Deshydro-
genase (LDH) was measured spectrophotometrically (at 412 nm
for CS and 340 nm for LDH) on cell lysates at 37uC in a cell
buffer (250 mM saccharose, 20 mM tris[hydroxymethyl]amino-
methane, 2 mM EGTA, 1 mg/ml bovine serum albumin, pH 7.2)
using a Beckman DU 640 spectrophotometer (Beckman Coulter).
Specific enzymatic activities were expressed in mIU (i.e.
nanomoles of 5,5-dithiobis(2-nitrobenzoic acid)/min/mg portein
for CS or nanomoles of NADH/min/mg protein for LDH). The
cellular protein content was determined using the Bicinchoninic
assay kit (Uptima, Interchim, Montluc¸on, France) with bovine
serum albumin as standard (All from Sigma-Aldrich, Saint Louis,
MO, USA, except Tris from Eurobio, Les Ulis, France). Results
were expressed as relative LDH to CS activities as an indicator of
global cell metabolism.
Lactate concentration in the culture media was determined by
spectrophotometry using appropriate enzymatic kits (Boehringer
Mannheim, Germany) on a Hitachi-Roche 917 (Roche Diagnos-
tics GmbH Mannheim, Germany) and normalized to total cell
numbers.
Microarray Analysis
cDNA from RO82W-1 cells were hybridized in duplicate on
human 4644,000 expression chips (Agilent Technologies, Santa
Clara, CA, USA) according to the manufacturer’s recommenda-
tions. Data are available in the GEO database (GSE 37017). The
Expression Analysis Systematic Explorer (EASE) and Gene Set
analysis were used to determine the statistically over-represented
and differentially expressed genes. Gene ontology enrichments in
gene lists were searched for by means of the GOMiner. The most
abundant gene ontology terms, representing at least 5% of the
genes in the lists, with p values lower than 0.05, were considered
for interpretation.
Statistical Analysis
Results were expressed as mean values 6 standard deviation
(SD). The statistical significance of observed variations was
assessed using the Mann-Whitney test. Differences were
considered significant at p,0.05. All analyses were performed
using StatView version 5.0 (SAS Institute, Cary, NC, USA).
Figure 3. ERRa inhibits LDHB promoter activity. (A) Different construction of the human LDHB promoter reporter plasmid. (B) RO82W-1 cells
were transfected with the indicated promoter constructs together with the expression plasmid of ERRa and/or PRC. Luciferase activity was
determined 48 h after transfection and normalized against renilla luciferase activity. Results, presented in Relative Light Units (RLU), are the mean
values6SD of three experiments performed in duplicate. *: p#0.05 versus cells transfected with plasmids controls and no ERRa or PRC.
doi:10.1371/journal.pone.0058683.g003
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Results
Expression of ERRa and LDH Genes in Human Thyroid
Tissues and Cell Lines
We studied the expression of ERRa and LDH in 30 normal or
tumoral human thyroid tissues and three human thyroid cancer
cell lines: RO82W-1, FTC-133, XTC.UC1.
The thyroid tissues and cell lines expressed the same LDH gene
profiles with higher copy numbers of LDHA than those of LDHB
(Figure 1A). The expression level of LDHA was four times higher in
FTC-133 and RO82W-1 cells than in XTC.UC1 cells. The
expression levels of LDHB were higher by factors of 3.56 in FTC-
133 cells and 1.60 in XTC.UC1 cells, compared to RO82W-1
cells. These results were confirmed at protein levels for LDHA,
LDHB (Figure S1). In thyroid tissues, the LDHA and LDHB
expression levels were similar in follicular, oncocytic tumors and
normal tissues (Figure 1B). The correlation between protein and
mRNA levels for LDHA and LDHB was less relevant, but related to
previous studies on cell metabolism where a mix between aerobic
and anaerobic glycolysis was described in normal and tumor cells
[21–22] (Figure S1).
Using the LDHA/LDHB expression ratio as an indicator of the
combined influence of the isoforms on LDH activity, we showed
that this ratio was higher for RO82W-1 cells than for FTC-133, or
XTC.UC1 cells (Figure 1C). In thyroid tissues the ratio was higher
for normal thyroid tissues than for follicular tumors or oncocytic
tumors (Figure 1D).Thus, the LDHA/LDHB ratio was similar in
follicular and oncocytic tumors and their corresponding cell line
models, FTC-133 and XTC.UC1.
We evaluated the glycolytic metabolism by lactate dehydroge-
nase activity (Figures 1E and 1F) and mitochondrial oxygen
consumption (Figures 1G and 1H). The relative LDH activity was
higher in RO82W-1 cells in which the oxygen consumption rate
was lowest. In contrast, the relative LDH activity of FTC-133 and
XTC.UC1 cells was 2 to 5 times lower than that of RO82W-1
cells, and the oxygen consumption rates were twice as high. These
findings suggest that FTC-133 and XTC.UC1 cells mainly use an
oxidative metabolism whereas RO82W-1 cells mainly depend on
anaerobic glycolysis. These results were supported by the
measurement of total lactate production in the culture media for
the three cell lines (Figure S1). In thyroid tissues, the relative LDH
activity was similar in normal thyroid and follicular tumors
whereas it was 40% lower in oncocytic tumors. Oxygen
consumption was 1.58 to 3.25 times higher in follicular and
oncocytic tumors, respectively, compared to control thyroid
tissues. Thus, oxidative metabolism appeared to be favored in
follicular and oncocytic thyroid tumors.
In all thyroid tissues and cell lines, the expression levels of ERRa
were overexpressed in samples with pronounced oxidative
metabolism (Figure 1A and 1B). ERRa levels were respectively
1.6 and 4 times higher in follicular and oncocytic tumors
compared to normal tissues. Similarly, ERRa levels were higher
in FTC-133 and XTC.UC1 cells than in RO82W-1 cells. All these
results were confirmed at the protein level (Figure S1).
ERRa Motifs in LDHA and LDHB Promoters
We examined the LDHA and LDHB promoters using ERRa
binding-site matrices described elsewhere [17]. The promoter
sequences, extracted from nucleotides 22000 to 21, starting from
the transcription starting site (TSS), were scanned for ERRa
binding sites. The bioinformatics search suggested that one region
between 2456/2448 for the LDHA promoter, and the three
regions between 2849/2841, 2560/2552 and 2118/2110 for
the LDHB promoter, were potential ERRa binding sites (p#0.05)
(Figure 2A).
We confirmed the physical association between ERRa and the
LDHB promoter in oncocytic cells (XTC.UC1) using the
chromatin immunoprecipitation (ChIP) assay with a polyclonal
ERRa antibody. We chose these cells because of their high
expression levels of ERRa (Figure 1A). A 12-fold enrichment of
the LDHB gene expression was observed compared to that of the
IgG fraction. No enrichment was observed on the LDHA promoter
(Figure 2B). These findings indicate that ERRa directly interacts
with the LDHB promoter but not that of LDHA.
Regulation of the LDHB Promoter by ERRa
To investigate the molecular mechanism of the transcriptional
activation of LDHB by ERRa, we built four constructions of
a genomic DNA fragment from the 59-flanking region of the
human LDHB gene into a luciferase plasmid (Figure 3A). We
transfected one of these four constructions with ERRa and/or
PRC in RO82W-1 thyroid cancer cells, which have low
mitochondrial mass and poor expression of ERRa and PRC
(Figure 3B). An overexpression of ERRa induced a 60% decrease
in transcriptional activity with p.LDHB-Luc 1188 which contains
the three potential ERREs. No change was observed with the
three other constructions, suggesting that only the ERRE1 (2849/
2841 region) is functional. Our earlier work indicated that PRC
could be a key partner in the action of ERRa [6,17]. We therefore
transfected PRC, either alone or with ERRa, into each of the four
constructions of the LDHB promoter. No effect on reporter activity
was observed after transfection with PRC alone. The forced
overexpression of ERRa and PRC reduced luciferase activity by
53% with the longest LDHB promoter but no interaction was
observed using the other promoters.
These results suggest that ERRa interacted with the 2849/
2841 region of the LDHB promoter and exerted a negative
transcriptional activity. The action of PRC in our model on the
LDHB promoter is either null or as a transcriptional coactivator of
ERRa.
ERRa Modulates LDH Activity
To investigate the role of ERRa and PRC in regulating LDHB
transcription, we overexpressed ERRa and/or PRC in RO82W-1
cells, which present low expression levels of endogenous ERRa and
PRC. Overexpression of ERRa, either alone or with PRC,
consistently decreased the expression of LDHB at mRNA and
protein levels whereas it had no effect on LDHA (Figure 4A and
Figure S2). Thus, the LDHA/LDHB mRNA expression ratios
Figure 4. ERRa modulates expression and activity of LDH. LDHA and LDHB expression levels were measured by quantitative real-
time PCR. The ratio of LDH activity to CS activity was determined under various conditions. Measurements were made 48 h after transfection or 10
days of treatment with XCT790 and results are presented relative to the control which was assigned a unit value. LDHA and LDHB expression levels,
the mean LDHA/LDHB ratio (A) and the relative LDH activity (B) for RO82W-1 cells transfected with 50 ng ERRa or 50 ng ERRa and 50 ng PRC or empty
vectors (Control). LDHA, LDHB expression levels and mean of the LDHA/LDHB ratio (C) and relative LDH activity (D) for FTC-133 cells treated with
XCT790 or vehicle (Control). LDHA, LDHB expression levels and mean of the LDHA/LDHB ratio (E) and relative LDH activity (F) for FTC-133 cells
transfected with control or ERRa siRNA. The results are the mean values6SD of three experiments performed in duplicate relative to controls. *:
p#0.05.
doi:10.1371/journal.pone.0058683.g004
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significantly increased by 56% when ERRa was overexpressed
(p,0.05) and by 96% when both ERRa and PRC were
overexpressed (p,0.05). Only the overexpression of both ERRa
and PRC significantly decreased LDH activity (p,0.05) (Fig. 4B).
We investigated the consequences of the inhibition of ERRa
and PRC on LDH activity in FTC-133 cells which present the
highest expression of endogenous ERRa in the three tumor cell
lines. The treatment of these cells with XCT790 significantly
increased the expression of LDHB at mRNA and protein levels
Figure 5. ERRa and PRC coregulate the cell cycle and metabolism in thyroid cells. RO82W-1 cells transfected with ERRa and PRC or empty
vector (Control) and analysed 72 h after transfection. Pangenomic microarray results for metabolism genes. Gene-expression levels are grouped by
class and ordered according to their mean log level of expression (A) or color-coded in the matrix from green (underexpression) to red
(overexpression) (B). Ten main gene ontologies (C). Cell proliferation and lactate levels in media (D).
doi:10.1371/journal.pone.0058683.g005
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and that of LDH activity by 36% (Figures 4C, 4D and Figure S2).
It had no effect on protein and mRNA levels for LDHA
(Figures 4C and Figure S2). Thus, the LDHA/LDHB expression
ratios decreased by 30%. The same results were obtained when we
inhibited ERRa with XCT790 and PRC with specific siRNA
(data not shown). To exclude the action of XCT790 on other
proteins, we confirmed these results by ERRa siRNA. The
inhibition of ERRa significantly increased the protein and mRNA
levels for LDHB but had no effect on protein and mRNA levels for
LDHA (Figure 4E and Figure S2); LDH activity increased by 50%
(Figure 4F).
Our results show that ERRa regulates LDH activity by direct
interaction with the LDHB promoter in cellular models of follicular
thyroid carcinoma, and that PRC may interact with ERRa to
decrease LDH activity and modulate the LDHA/LDHB expres-
sion ratio.
ERRa Coregulates the Cell Cycle and the Metabolism
Since a significant decrease in LDH activity was observed only
when combining the overexpressions of PRC and ERRa, we chose
to explore differential gene expression by cDNA microarray
comparing RO82W-1 cells transfected with both ERRa and PRC,
and cells transfected with control plasmids. The pangenomic
microarray data showed that the overexpression of ERRa and
PRC induced the differential expression of 553 genes (Figure 5A
and 5B). The main gene ontology showed a significant over-
expression of genes implicated in the cell cycle, regulation of cell
proliferation and G1/S transition of the mitotic cell cycle when
ERRa and PRC were overexpressed (Figure 5C). Nevertheless,
RO82W-1 cells transfected with control plasmids or both PRC
and ERRa plasmids during 72 h had the same proliferative
statuses (Figure 5D). We found an overexpression of genes
implicated in estrogen receptor signaling due to the high degree
of sequence identity between ERR and the estrogen receptor.
Moreover, we found an overexpression of the respiratory electron
transport chain as described previously [6].
Of the 553 genes with differential expressions due to ERRa and
PRC, 288 were involved in the metabolism. Among these 288
genes, we found a positive regulation for 40% of the genes of
respiratory chain and a negative regulation for 86% of the genes of
TCA and anaerobic glycolysis (Figure 5A). We verified that the
lactate production was not increased when the cells were
transfected with ERRa and PRC (Figure 5D).
Discussion
The modification of cellular metabolism in tumors has recently
been characterized as one of the major alterations of tumor cells
[23]. Indeed, tumor cells, which have an altered carbohydrate
metabolism, produce ATP from glucose through oxidative
phosphorylation (OXPHOS) and anaerobic glycolysis even under
normal oxygen pressures. This metabolic strategy offers tumors
a selective advantage by satisfying the high ATP demands,
facilitating the macromolecular biosynthesis required by rapidly
proliferating tumors, and allowing NAD+ production in the
absence of mitochondrial oxidation.
The regulation of cell metabolism requires the expression of
a large number of genes encoded by the nuclear and the
mitochondrial genome. The coordination of these genes depends
on transcription factors among which ERRa appears to be
essential [24]. ERRa is known to coregulate and coordinate gene-
encoding enzymes of the biochemical pathways involved in the
generation of energy from glucose via OXPHOS. Our findings
indicate that ERRa may also regulate anaerobic glycolysis via
LDH activity in thyroid tumors. The Warburg effect having been
recently revisited, a more realistic description of cancer cell
metabolism suggests that oxidative phosphorylation and anaerobic
glycolysis cooperate to sustain energy needs during tumorigenesis
[25]. In breast cancer it has been shown that miRNA-378
regulates the metabolic switch via the ERRc-PGC1b complex,
which promotes oxidative metabolism, and the ERRa-PGC1b
complex, which favors activation of the glycolytic pathway [26].
We have shown that ERRa controls the cell cycle and promotes
the efficiency of oxidative phosphorylation by interfering with
PRC coactivators and according to the metabolic status of the cells
in thyroid tumors [6]. Our study of LDH activity and oxygen
consumption shows that, compared to normal tissues and follicular
tumors, oncocytic tumors mainly depend on oxidative metabolism.
This type of altered metabolism has already been described in
other tumors, such as hepatomas, melanomas and lung carcino-
mas [27,28]. This oxidative metabolism could be orchestrated by
ERRa. Indeed, the expression of the ERRa gene is greater in
oncocytic tumors than in normal thyroid tissues and follicular
tumors. Hypothesizing that ERRa coregulates OXPHOS and
glycolytic pathways in an aerobic environment, we investigated the
regulation of the glycolytic enzyme LDH in cellular models of
thyroid tumors. We choose cellular models presenting oxidative or
glycolytic metabolism, to explore mechanisms for oxidative
maintenance in XTC.UC1 and FTC133, and the role of ERRa
in RO82W-1 metabolic reversion. Investigating the promoters of
the LDHA and LDHB genes we found responsive elements for
ERRa in both genes. However, chromatin-immunoprecipitation
studies and experiments involving transient transfection confirmed
the functional interaction only for the LDHB gene. These results
are in accordance with a recent study showing that LDHB is
regulated by ERRa and Prox1 whereas LDHA expression only
depends on Prox1. Interestingly, Prox1 has been shown to inhibit
the activity of the ERRa-PGC-1a complex in liver cells [29]. In
contrast, it has been found that ERRa activates the LDHA gene
promoter through ERRE in HepG2 human liver cells or MCF7
human breast cancer cells [4]. This divergent regulation of
bioenergetic functions via the action of ERRa transcriptional
complex highlights the role of the cofactors in the context of
proliferative cells.
Lactate dehydrogenase is composed of two subunits, M and H,
which enter into five different combinations. The expression levels
of LDHA and LDHB expression determine the cellular isozyme
pattern [10]. A study based on a mathematical model of the LDH
reaction concluded that the decisive parameter was the total LDH
activity and not the isoenzyme pattern [30]. The situation is quite
different during metabolic transitions in energy metabolism, in
particular when the glycolytic flux changes as it does in tumors
[31]. In such cases, the LDH isoform ratio may serve as an
indicator of the relative flux through the aerobic and anaerobic
systems. Indeed, in our study, oncocytic and follicular tumors were
more dependent on oxidative metabolism, expressed more ERRa,
and had a lower LDHA/LDHB ratio than control thyroid tissues.
The results were similar for thyroid cell lines presenting an ERRa
expression and an LDHA/LDHB ratio in relation to their
metabolic status. We found a functional ERRE on the LDHB
promoter that negatively regulated LDHB expression. Surprising-
ly, in thyroid tissues and cell lines, the expression levels of ERRa
and LDHB were correlated. We hypothesised that this coregula-
tion could be orchestrated by mTOR, which is often deregulated
in thyroid tumors [32]. Indeed, mTOR has been identified as
a positive regulator of ERRa and LDHB [15,33]. Thus, ERRa and
LDHB expression may be coregulated independently of the
potential regulation of LDHB by ERRa. Contrary to other studies,
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the LDHA promoter has no functional ERRE in our cellular
models [4]. We postulate that difference in the cofactors (PGC-
1alpha/PRC ratio) in our tumor cells may have an impact on the
expression of LDH genes. We have shown that our three cell lines
expressed 3.6 to 8 times more PRC than PGC1a [6]. PRC and
ERRa are known to play a role in the transition from the G1
phase to the S phase of the cell cycle [34,35], and to regulate the
energy needs of the cells. Our study showed an overexpression of
genes implicated in the regulation of the cell cycle, with a similar
proliferation of cells after 72 h of transfection with ERRa and
PRC. We need to confirm these findings by using cell lines with
stable transfection of ERRa and PRC and evaluating cell
proliferation after a longer period. Our previous work showed
that the inhibition of ERRa by XCT790 decreased cell pro-
liferation after 10 days of treatment (6). Thus, the transition and
modification of tumor cell proliferation could be orchestrated by
the ERRa-PRC complex by two mechanisms: regulation of the
cellular energy metabolism and alteration of the LDH subunit
composition. The down-expression of LDHB could transform the
LDH isoenzyme into the LDH5 isoenzyme containing only the M
subunits coded by the LDHA gene known to be linked to metastatic
progression [36,37]. A similar change in the isoform pattern
adapting tumor cells to environmental conditions has been
described for hexokinase and phospho-fructokinase, two enzymes
of the glycolytic pathway [38,39]. Moreover, the release of lactate
decreases the pH in the extracellular space, destroying adjacent
normal cells, degrading the extracellular matrix and facilitating
tumor invasion [13]. Our findings suggest that ERRa may
influence tumor aggressiveness by metabolic modification and
modulation of the LDHA/LDHB expression ratio.
Our observations show that the ERRa transcriptional complex
is important in the induction of a metabolic shift in thyroid cell
lines. Further experiments are needed to validate ERRa as a key
factor of metabolic shift in thyroid tumors event though our results
argue in favor of a pivotal role of ERRa for the regulation of both
oxidative and glycolytic metabolism for oxydative thyroid tumors.
Supporting Information
Figure S1 Basal protein levels of LDH, ERRa and lactate
production. Quantitative protein level of LDHA, LDHB and
ERRa in thyroid cell lines (A) and thyroid tissues (B) were
determined by western blot and presented relative to the control
(b-Actin) that was assigned a value of unity (n = 2). (C) Total
lactate production by thyroid cell lines (n = 3 in triplicate).
(TIF)
Figure S2 ERRa modulates protein levels of LDHB (A)
Quantitative protein levels of LDHA, LDHB and ERRa were
determined for RO82W-1 cells transfected with 50 ng ERRa or
50 ng ERRa and 50 ng PRC or empty vectors (Control).
Measurements were made 48 h after transfection by western blot
and presented relative to the control (b-Actin) that was assigned
a value of unity (n = 2). (B) Quantitative protein levels of LDHA,
LDHB and ERRa were determined for FTC-133 cells treated for
10 days with XCT790 or vehicle (Control). Measurements were
made 48 h after transfection by western blot and presented
relative to the control (b-Actin) that was assigned a value of unity
(n = 2).
(TIF)
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